Patents by Inventor James Sheppeck

James Sheppeck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulators of the glucocorticoid receptor, AP-1, and/or NF-?B activity and use thereof
    Patent number: 7625921
    Abstract: A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR1R2 or CH2NR1R2 and where at least one of X1-X8 is N, and R, Ra, Rb, Rc and Rd are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
    Type: Grant
    Filed: January 13, 2005
    Date of Patent: December 1, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jingwu Duan, James Sheppeck, Bin Jiang, John L. Gilmore
  • Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-?B activity and use thereof
    Patent number: 7605264
    Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or stereoisomers or prodrugs or solvates or pharmaceutically acceptable salts thereof, wherein A, B, J, K, Z, R, Ra, Rb, Rc, and Rd, are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
    Type: Grant
    Filed: January 13, 2005
    Date of Patent: October 20, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: David S. Weinstein, James Sheppeck, John L. Gilmore
  • Modulators of the glucocorticoid receptor, AP-1, and/or NF-?B activity and use thereof
    Patent number: 7569689
    Abstract: A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR1R2 or CH2NR1R2 and where at least two of X1-X4 and/or X5-X8 is N or NR18, and R, Ra, Rb, Rc, Rd, R1, R2 and R18 are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
    Type: Grant
    Filed: January 13, 2005
    Date of Patent: August 4, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jingwu Duan, Bin Jiang, James Sheppeck, John L. Gilmore
  • Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-?B activity and use thereof
    Patent number: 7544808
    Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein B, J, K, Z, R, Ra, Rb, Rc, Rd, Rq, Rw, m and n are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: June 9, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: David S. Weinstein, John L. Gilmore, James Sheppeck, Bingwei Vera Yang, Soong-Hoon Kim, Wayne Vaccaro
  • Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-?B activity and use thereof
    Patent number: 7361654
    Abstract: The present invention relates to new class of non-steroidal compounds which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory- and immune-associated diseases, and have the structure including all stereoisomers thereof, tautomers thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein X is selected from N, O, and S; Y is N or CR6; Z is a ring; and where R, Ra, Rb, Rc, Rd, R1, R2, R3, R4, and R5 are as defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising such compounds.
    Type: Grant
    Filed: January 12, 2006
    Date of Patent: April 22, 2008
    Assignee: Bristol-Myers Squibb Co.
    Inventors: James Sheppeck, T. G. Murali Dhar, Lidia Doweyko, John Gilmore, David Weinstein, Hai-Yun Xiao, Bingwei V. Yang, Arthur M. Doweyko
  • TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
    Publication number: 20070270453
    Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein B, J, K, Z, R, Ra, Rb, Rc, Rd, Rq, Rw, m and n are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
    Type: Application
    Filed: July 5, 2007
    Publication date: November 22, 2007
    Inventors: David Weinstein, John Gilmore, James Sheppeck, Bingwei Yang, Soong-Hoon Kim, Wayne Vaccaro
  • Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-?B activity and use thereof
    Patent number: 7253283
    Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein B, J, K, Z, R, Ra, Rb, Rc, Rd, Rq, Rw, m and n are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
    Type: Grant
    Filed: January 13, 2005
    Date of Patent: August 7, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: David S. Weinstein, John L. Gilmore, James Sheppeck, Bingwei Vera Yang, Soong-Hoon Kim, Wayne Vaccaro
  • Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-? converting enzyme (TACE)
    Patent number: 7211671
    Abstract: The present invention describes novel 1,3-dihydro-imidazol-2-one or 1,3-dihydro-imidazol-2-thione compounds of formula (I): or a stereoisomer or pharmaceutically acceptable salt or solvate thereof, wherein A, L R1, R2, R3 and R4 are defined in the present specification, which are useful as selective inhibitors of MMP, TACE, aggrecanase or a combination thereof. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.
    Type: Grant
    Filed: September 21, 2004
    Date of Patent: May 1, 2007
    Assignee: Bristol Myers Squibb Company
    Inventors: James Sheppeck, John L. Gilmore, Xiao-Tao Chen, Xiaohua He
  • Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)
    Patent number: 7132432
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein the variables L, Z0, R1, R4, R5, and R11 are defined are as defined herein, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), aggrecanase, or a combination thereof.
    Type: Grant
    Filed: June 2, 2004
    Date of Patent: November 7, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jingwu Duan, Chu-Biao Xue, James Sheppeck, Bin Jiang, Lihua Chen
  • Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof
    Publication number: 20060154973
    Abstract: The present invention relates to new class of non-steroidal compounds which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory- and immune-associated diseases, and have the structure including all stereoisomers thereof, tautomers thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein X is selected from N, O, and S; Y is N or CR6; Z is a ring; and where R, Ra, Rb, Rc, Rd, R1, R2, R3, R4, and R5 are as defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
    Type: Application
    Filed: January 12, 2006
    Publication date: July 13, 2006
    Inventors: James Sheppeck, T.G. Dhar, Lidia Doweyko, John Gilmore, David Weinstein, Hai-Yun Xiao, Bingwei Yang, Arthur Doweyko
  • Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-? converting enzyme
    Patent number: 7074810
    Abstract: The present application describes novel hydantoin derivatives of formula (I): or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, L, and R11 are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), aggrecanase, or a combination thereof.
    Type: Grant
    Filed: October 3, 2003
    Date of Patent: July 11, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Bryan W. King, James Sheppeck, John L. Gilmore
  • Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-? converting enzyme (TACE)
    Patent number: 7041693
    Abstract: The present application describes novel hydantoin derivatives of formula (I): or pharmaceutically acceptable salt or prodrug forms thereof, wherein L, Z0, R1, R4, R5, and R11 are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), aggrecanase, or a combination thereof.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: May 9, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventor: James Sheppeck
  • Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof
    Publication number: 20050187242
    Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein B, J, K, Z, R, Ra, Rb, Rc, Rd, Rq, Rw, m and n are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
    Type: Application
    Filed: January 13, 2005
    Publication date: August 25, 2005
    Inventors: David Weinstein, John Gilmore, James Sheppeck, Bingwei Yang, Soong-Hoon Kim, Wayne Vaccaro
  • Modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof
    Publication number: 20050182082
    Abstract: A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR1R2 or CH2NR1R2 and where at least one of X1-X8 is N, and R, Ra, Rb, Rc and Rd are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
    Type: Application
    Filed: January 13, 2005
    Publication date: August 18, 2005
    Inventors: Jingwu Duan, James Sheppeck, Bin Jiang, John Gilmore
  • Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof
    Publication number: 20050182083
    Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or stereoisomers or prodrugs or solvates or pharmaceutically acceptable salts thereof, wherein A, B, J, K, Z, R, Ra, Rb, Rc, and Rd, are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
    Type: Application
    Filed: January 13, 2005
    Publication date: August 18, 2005
    Inventors: David Weinstein, James Sheppeck, John Gilmore
  • Modulators of the glucocorticoid receptor, AP-1, and/or NF-kappaB activity and use thereof
    Publication number: 20050176716
    Abstract: A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR1R2 or CH2NR1R2 and where at least two of X1-X4 and/or X5-X8 is N or NR18, and R, Ra, Rb, Rc, Rd, R1, R2 and R18 are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
    Type: Application
    Filed: January 13, 2005
    Publication date: August 11, 2005
    Inventors: Jingwu Duan, Bin Jiang, James Sheppeck, John Gilmore
  • Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
    Publication number: 20050171096
    Abstract: The present application describes novel hydantoin derivatives of formula (I): or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, R1, R2, R3, R4, R5, R6, R7, R11, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), aggrecanase, or a combination thereof.
    Type: Application
    Filed: March 30, 2005
    Publication date: August 4, 2005
    Inventors: James Sheppeck, Jingwu Duan, Chu-Biao Xue, Zelda Wasserman
  • Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
    Publication number: 20050075384
    Abstract: The present invention describes novel 1,3-dihydro-imidazol-2-one or 1,3-dihydro-imidazol-2-thione compounds of formula (I): or a stereoisomer or pharmaceutically acceptable salt or solvate thereof, wherein A, L R1, R2, R3 and R4 are defined in the present specification, which are useful as selective inhibitors of MMP, TACE, aggrecanase or a combination thereof. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.
    Type: Application
    Filed: September 21, 2004
    Publication date: April 7, 2005
    Inventors: James Sheppeck, John Gilmore
  • Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)
    Publication number: 20040254231
    Abstract: The present invention provides compounds of Formula (I): 1
    Type: Application
    Filed: June 2, 2004
    Publication date: December 16, 2004
    Inventors: Jingwu Duan, Chu-Biao Xue, James Sheppeck, Bin Jiang, Lihua Chen
  • Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme
    Publication number: 20040116491
    Abstract: The present application describes novel hydantoin derivatives of formula (I): 1
    Type: Application
    Filed: October 3, 2003
    Publication date: June 17, 2004
    Inventors: Bryan W. King, James Sheppeck, John L. Gilmore